We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

Merck & Co., Inc. (NYSE:MRK) is advancing the development of enlicitide, an oral PCSK9 inhibitor positioned as the most potent oral LDL-lowering medicine. This drug is designed to offer a cost ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

For now though, any threat from Merck's drug is speculative ... AstraZeneca meanwhile is also working on an oral PCSK9 inhibitor that it acquired from Dogma Therapeutics last year and is in ...

AZ is now planning to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with MSD – known as Merck & Co in ...

Antonio Gotto serves on the board of directors of Aegerion Pharmaceuticals, Arisaph Pharmaceuticals and Esperion Therapeutics; as a consultant for Kowa and Merck; and on an advisory board for ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best blue chip stocks to buy under $100. Blue chip stocks have long been considered the gold ...

Merck (MRK) announced the U.S. FDA has accepted for priority review a supplemental new drug application seeking approval of Welireg, Merck’s ...